- Home
- SLNO vs ADMA Comparison
SLNO vs ADMA Comparison
Compare SLNO & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLNO
- ADMA
- Stock Information
- Founded
- SLNO 1999
- ADMA 2004
- Country
- SLNO United States
- ADMA United States
- Employees
- SLNO N/A
- ADMA N/A
- Industry
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLNO Health Care
- ADMA Health Care
- Exchange
- SLNO Nasdaq
- ADMA Nasdaq
- Market Cap
- SLNO 3.8B
- ADMA 3.7B
- IPO Year
- SLNO 2014
- ADMA N/A
- Fundamental
- Price
- SLNO $65.46
- ADMA $14.36
- Analyst Decision
- SLNO Strong Buy
- ADMA Strong Buy
- Analyst Count
- SLNO 9
- ADMA 3
- Target Price
- SLNO $116.78
- ADMA $27.67
- AVG Volume (30 Days)
- SLNO 1.7M
- ADMA 3.2M
- Earning Date
- SLNO 11-05-2025
- ADMA 11-06-2025
- Dividend Yield
- SLNO N/A
- ADMA N/A
- EPS Growth
- SLNO N/A
- ADMA 469.09
- EPS
- SLNO N/A
- ADMA 0.85
- Revenue
- SLNO $32,656,999.00
- ADMA $474,174,000.00
- Revenue This Year
- SLNO N/A
- ADMA $21.17
- Revenue Next Year
- SLNO $182.29
- ADMA $26.03
- P/E Ratio
- SLNO N/A
- ADMA $16.99
- Revenue Growth
- SLNO N/A
- ADMA 43.58
- 52 Week Low
- SLNO $41.50
- ADMA $13.50
- 52 Week High
- SLNO $90.32
- ADMA $25.67
- Technical
- Relative Strength Index (RSI)
- SLNO 51.66
- ADMA 39.48
- Support Level
- SLNO $63.02
- ADMA $14.28
- Resistance Level
- SLNO $72.88
- ADMA $15.60
- Average True Range (ATR)
- SLNO 4.25
- ADMA 0.55
- MACD
- SLNO 1.03
- ADMA 0.08
- Stochastic Oscillator
- SLNO 56.61
- ADMA 30.06
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.